Yesterday was a sad day when my thoughts were with A Mesowarrior as she gained her wings.
But today I must bounce back and get back to fighting for the future. For the cure.
It doesn’t discriminate even famous people are falling with mesothelioma as we heard of the death of Joe Sample, a fine piano player and talented songwriter who was a founding member of the Jazz Crusaders, has died from complications due to lung cancer at the age of 75.
Among the hits he co-wrote with Will Jennings were the songs Street Life and One Day I’ll Fly Away (for Randy Crawford) and Soul Shadows (for Bill Withers).
It makes me so angry as we have been losing a Mesowarrior each day this week. So much pain and heart break.
On Face Book Asbestos Hunter says — Asbestos still remains in many materials which could be right under our very noses. Have an inspection performed by an asbestos professional; awareness leads to prevention.
Great advice but we need more we need a duty to care for our Homes.I have been concentrating more on the cure and treatment for Mesothelioma. I feel we should get also back the fight to make our homes safe and and to back the training companies like IATP— IATP is supporting the HSE’s Asbestos: Hidden Killer campaign, which is seeking to raise awareness of the dangers of asbestos among tradesmen and women. Currently, each week, roughly 20 tradesmen die because of exposure to asbestos; to see how asbestos can affect you,
The GMB wrote last year —-GMB has major concerns with the manner in which asbestos is managed in schools as it is obvious that that it is often unclear who the duty holder with legal responsibilities is. As more schools leave the control of local authorities to become academies or free schools there is a very real danger that the little knowledge over asbestos within school buildings will be lost.
We need to protect our Children from Asbestos. http://www.asbestosexposureschools.co.uk/
Nancy Meredith is a blog and web content writer with more than 20 years of professional experience in the Information Technology industry. She has been writing about Mesothelioma for 4 years has written a lovely piece about me and my trial.
FDA Approves Breakthrough Cancer Drug for Melanoma; Mavis Nye Participates in Mesothelioma Trial for Same Drug in UK
Merck just broke away from the rest of the pack in the race to bring a breakthrough cancer treatment to patients in the United States, and is poised to do the same in Europe. The U.S. Food and Drug Administration announced last week that it has granted accelerated approval to Merck’s Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma. Finally, mesothelioma patients, and patients of countless other cancers, may also have access to what’s being touted as the “new breed of cancer treatment.”
The FDA reports that Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the body’s immune system from attacking melanoma cells. In effect, the drug turns cancer patients’ immune systems back on. The approval was granted, according to the FDA, when Merck presented “evidence that the drug may offer a substantial improvement over available therapies.” In the results of a clinical trial, nearly 24 percent of the patients had their tumors shrink, lasting up to 8.5 months, and for some, the shrinkage continued beyond this period.
“KEYTRUDA embodies Merck’s unwavering commitment to pursue breakthrough science to help people who are facing the most challenging diseases,” said Kenneth C. Frazier, chairman and chief executive officer at Merck, in the press release announcing the drug’s approval.
PD-L1, or programmed death-ligand 1, is a protein that has been shown to play a role in suppressing the immune system during cancer and other diseases. According to Merck, Keytruda blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
“Our new ability to target the PD-1 pathway with KEYTRUDA is a very exciting step in the immunotherapy field,” said Dr. Omid Hamid, Director of the Melanoma Center at The Angeles Clinic and Research Institute, and a principal investigator for the drug’s clinical program.
Mavis Nye of England Chronicles Her “Brilliant Results” as She Helps Lead the Way for Mesothelioma Research
Keytruda, formerly known as MK-3475, is currently undergoing clinical trials throughout the world for a variety of cancers, including mesothelioma, breast, colorectal and kidney. A search of ClinicalTrials.gov yields a list of 26 clinical trials throughout the U.S., the UK and in Australia, Austria, and Belgium, as well as other countries.
Mavis Nye, of Seasalter, England, a five-year mesothelioma survivor, is a patient in the clinical trial of MK-3475 at The Royal Marsden in the UK. In May, we reported Mavis’ acceptance into the trial. Since then, she has been meticulously chronicling her experience with the trial in her blog, Living with Mesothelioma.
After over three months of treatment and constant monitoring by the medical team at Marsden, Mavis told MesotheliomaHelp that she has “no sickness, and I feel so well.”
When Mavis was accepted into this trial, she said she “signed her body over to them,” and she has absolutely no regrets. She feels like a different person than the one who walked through the door months ago. She states in her blog, that then, “I was a mess, I know.”
“I’m feeling very well as my immune system has been turned back on by the drug,” Mavis said in an email. “I have more energy, and because my appetite has returned, I cook more. I heal very quickly, I walk unaided now – no stick or walking aid.” [Previously, Mavis was using a walking stick to keep her steady, due to the damage to her nervous system, known as peripheral neuropathy, from chemotherapy.]
Mavis initially experienced a few side effects, including lack of energy, a runny nose and cough. As Mavis reported on her blog after three weeks on the medicine, “When you think how bad chemo was, this is a party.” MK-3475 is not a chemotherapy drug, and now, Mavis reports that she has no side effects.
“The results have been brilliant.”
The best news of all, is that after years of fighting to keep her mesothelioma growth at bay, Mavis reports the drug is shrinking her tumors. In fact, in the latest scan, the doctors could tell just by looking at the tumor on x-ray, without even having to measure, that it is continuing to shrink. Prior to entry into the trial, Mavis reports via her blog that her tumors were growing two mm every three months, “just getting bigger and bigger.”
“A scan showed shrinkage in all areas after eight weeks of four drug sessions,” Mavis said. “After six drug sessions, a scan this week has shown more shrinkage without it even being measured.”
The mesothelioma trial is now closed to patients. Mavis, always the advocate, said in her June 30 blog, “So disappointed that other Warriors won’t get the chance [to participate in the trial]. I wish they would up the spaces from 375 around the world.
Now, she is focused on getting the drug to patients in the UK. “I hope this is fast-tracked in the UK. Only 3 places for Mesothelioma [trial] is not enough, and so they should now trial it for more Mesowarriors. I think that should be sped up.”
“This will give me more living, no one knows how long for as I’m leading the way now,” says Mavis in her Sept. 11 article in her blog. “Writing my own rule book here.”
Note: Bristol-Myers Squibb and partner Ono Pharmaceutical have filed a lawsuit against Merck claiming patent infringement of Keytruda. According to PMLive, the new drug violates a patent assigned to Ono and licensed by Bristol-Myers Squibb entitled ‘Immunopotentiative composition.’ Merck claims the suit is without merit.
Read more: http://mesotheliomahelp.net/blog/2014/09/fda-approves-breakthrough-cancer-drug-melanoma-mavis-nye-participates-mesothelioma-trial-drug-uk#ixzz3DSTnWGdy
Rays Blog http://mesoandme.wordpress.com/2014/09/15/monday-99/